tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Jul 14;8(7)
fab336.
doi: 10.1093/ofid/ofab336. eCollection 2021 Jul.
Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients
Vafa Bayat[SUP] 1 [/SUP], Russell Ryono[SUP] 1 [/SUP], Steven Phelps[SUP] 1 [/SUP], Eugene Geis[SUP] 1 [/SUP], Farshid Sedghi[SUP] 1 [/SUP], Payam Etminani[SUP] 1 [/SUP], Mark Holodniy[SUP] 2 3 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has led to a surge in clinical trials evaluating investigational and approved drugs. Retrospective analysis of drugs taken by COVID-19 inpatients provides key information on drugs associated with better or worse outcomes.
Methods: We conducted a retrospective cohort study of 10 741 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 days of admission to compare risk of 30-day all-cause mortality in patients receiving ondansetron using multivariate Cox proportional hazard models. All-cause mortality, length of hospital stay, adverse events such as ischemic cerebral infarction, and subsequent positive COVID-19 tests were measured.
Results: Administration of ≥8 mg of ondansetron within 48 hours of admission was correlated with an adjusted hazard ratio for 30-day all-cause mortality of 0.55 (95% CI, 0.42-0.70; P < .001) and 0.52 (95% CI, 0.31-0.87; P = .012) for all and intensive care unit-admitted patients, respectively. Decreased lengths of stay (9.2 vs 11.6; P < .001), frequencies of subsequent positive SARS-CoV-2 tests (53.6% vs 75.0%; P = .01), and long-term risks of ischemic cerebral ischemia (3.2% vs 6.1%; P < .001) were also noted.
Conclusions: If confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations.
Keywords: coronavirus; nausea; pneumonia; viral; vomiting.
. 2021 Jul 14;8(7)
fab336.doi: 10.1093/ofid/ofab336. eCollection 2021 Jul.
Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients
Vafa Bayat[SUP] 1 [/SUP], Russell Ryono[SUP] 1 [/SUP], Steven Phelps[SUP] 1 [/SUP], Eugene Geis[SUP] 1 [/SUP], Farshid Sedghi[SUP] 1 [/SUP], Payam Etminani[SUP] 1 [/SUP], Mark Holodniy[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34307731
- PMCID: PMC8294673
- DOI: 10.1093/ofid/ofab336
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has led to a surge in clinical trials evaluating investigational and approved drugs. Retrospective analysis of drugs taken by COVID-19 inpatients provides key information on drugs associated with better or worse outcomes.
Methods: We conducted a retrospective cohort study of 10 741 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 days of admission to compare risk of 30-day all-cause mortality in patients receiving ondansetron using multivariate Cox proportional hazard models. All-cause mortality, length of hospital stay, adverse events such as ischemic cerebral infarction, and subsequent positive COVID-19 tests were measured.
Results: Administration of ≥8 mg of ondansetron within 48 hours of admission was correlated with an adjusted hazard ratio for 30-day all-cause mortality of 0.55 (95% CI, 0.42-0.70; P < .001) and 0.52 (95% CI, 0.31-0.87; P = .012) for all and intensive care unit-admitted patients, respectively. Decreased lengths of stay (9.2 vs 11.6; P < .001), frequencies of subsequent positive SARS-CoV-2 tests (53.6% vs 75.0%; P = .01), and long-term risks of ischemic cerebral ischemia (3.2% vs 6.1%; P < .001) were also noted.
Conclusions: If confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations.
Keywords: coronavirus; nausea; pneumonia; viral; vomiting.